Form 4: United Therapeutics CFO Sells Shares Under 10b5-1 Plan

United Therapeutics CFO James Edgemond exercised stock options and sold 21,000 shares of common stock for over $446 per share under a pre-arranged trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), exercised 21,000 stock options at an exercise price of $146.03 per share on November 10, 2025.
• Concurrently, Mr. Edgemond sold 21,000 shares of common stock in multiple transactions on November 10, 2025.
• The sales were executed at weighted average prices ranging from $446.5087 to $455.8295 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on August 5, 2025.
• Following these transactions, Mr. Edgemond's direct beneficial ownership of common stock decreased to 8,118 shares, and his derivative beneficial ownership of stock options decreased to 10,312.

Sentiment

Score: 5

Explanation: The transaction involves an insider selling a significant number of shares, which can be viewed negatively. However, it was executed under a pre-arranged 10b5-1 plan, mitigating the immediate negative signal. The high sale prices are positive for the individual, but neutral for the company's immediate prospects.

Positives

• The sale prices for the common stock were significantly higher than the option exercise price of $146.03, indicating a profitable transaction for the insider.
• The transactions were executed under a Rule 10b5-1 trading plan, which suggests a pre-scheduled sale rather than a reaction to immediate market conditions or non-public information.

Negatives

• An insider, the CFO, sold a substantial number of shares (21,000 shares), which could be interpreted as a reduction in personal exposure to the company's stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider selling as a slight negative signal, though the pre-arranged nature of the 10b5-1 plan lessens its impact compared to unscheduled sales.

Key Dates

Recommendation

While the CFO sold a substantial number of shares, the transaction was pre-scheduled under a 10b5-1 plan, which typically reduces the immediate negative signaling effect of insider selling. The high sale prices indicate strong stock performance, but the sale itself doesn't provide new fundamental information to warrant a change in investment thesis. Investors should hold and monitor future company performance and other insider activity.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Share Sale, CFO, James Edgemond, 10b5-1 Plan, Beneficial Ownership